Search

Your search keyword '"Blay, Jean‐Yves"' showing total 3,362 results
Start Over Author "Blay, Jean‐Yves"
3,362 results on '"Blay, Jean‐Yves"'

2. Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants

Author

Chalouni, Mathieu, Loubet, Paul, Lhomme, Edouard, Ninove, Laetitia, Barrou, Benoit, Blay, Jean-Yves, Hourmant, Maryvonne, de Seze, Jérome, Laville, Martine, Laviolle, Bruno, Lelièvre, Jean-Daniel, Morel, Jacques, Quoc, Stéphanie Nguyen, Spano, Jean-Philippe, Terrier, Benjamin, Thiebaut, Anne, Viallard, Jean-Francois, Vrtovsnik, François, Circosta, Sophie, Barquin, Aude, Gharib, Mariam, Tartour, Eric, Parfait, Béatrice, Thiébaut, Rodolphe, Meyer, Laurence, de Lamballerie, Xavier, Launay, Odile, and Wittkop, Linda

Published
2024
Full Text
View/download PDF

3. EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

Author

Tagliamento, Marco, Morfouace, Marie, Loizides, Charalambos, Oliveira, Julio, Greillier, Laurent, Raimbourg, Judith, Toffart, Anne-Claire, Chatellier, Thierry, Cloarec, Nicolas, Sullivan, Ivana, Brasiuniene, Birute, Duruisseaux, Michael, Oselin, Kersti, Robert, Marie-Sophie, Fernandes, Carolina, Poncin, Arnaud, Blay, Jean-Yves, Besse, Benjamin, and Girard, Nicolas

Published
2024
Full Text
View/download PDF

4. Guiding principles on the education and practice of theranostics

Author

Pascual, Thomas N. B., Paez, Diana, Iagaru, Andrei, Gnanasegaran, Gopi, Lee, Sze Ting, Sathekge, Mike, Buatti, John M., Giammarile, Francesco, Al-Ibraheem, Akram, Pardo, Manuela Arevalo, Baum, Richard P., De Bari, Berardino, Ben-Haim, Simona, Blay, Jean-Yves, Brink, Anita, Estrada-Lobato, Enrique, Fanti, Stefano, Golubic, Anja Tea, Hatazawa, Jun, Israel, Ora, Kiess, Ana, Knoll, Peter, Louw, Lizette, Mariani, Giuliano, Mirzaei, Siroos, Orellana, Pilar, Prior, John O., Urbain, Jean-Luc, Vichare, Shrikant, Vinjamuri, Sobhan, Virgolini, Irene, and Scott, Andrew M.

Published
2024
Full Text
View/download PDF

5. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.

Author

Subbiah, Vivek, Kreitman, Robert J, Wainberg, Zev A, Gazzah, Anas, Lassen, Ulrik, Stein, Alexander, Wen, Patrick Y, Dietrich, Sascha, de Jonge, Maja JA, Blay, Jean-Yves, Italiano, Antoine, Yonemori, Kan, Cho, Daniel C, de Vos, Filip YFL, Moreau, Philippe, Fernandez, Elena Elez, Schellens, Jan HM, Zielinski, Christoph C, Redhu, Suman, Boran, Aislyn, Passos, Vanessa Q, Ilankumaran, Palanichamy, and Bang, Yung-Jue

Subjects
Humans, Glioma, Adenocarcinoma, Imidazoles, Pyridones, Pyrimidinones, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols, Mutation, Clinical Research, Cancer, Hematology, Brain Cancer, Brain Disorders, Rare Diseases, Digestive Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Medical and Health Sciences, Immunology
Abstract

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers: anaplastic thyroid carcinoma (n = 36), biliary tract cancer (n = 43), gastrointestinal stromal tumor (n = 1), adenocarcinoma of the small intestine (n = 3), low-grade glioma (n = 13), high-grade glioma (n = 45), hairy cell leukemia (n = 55) and multiple myeloma (n = 19). The primary endpoint of investigator-assessed overall response rate in these cohorts was 56%, 53%, 0%, 67%, 54%, 33%, 89% and 50%, respectively. Secondary endpoints were median duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. Median DoR was 14.4 months, 8.9 months, not reached, 7.7 months, not reached, 31.2 months, not reached and 11.1 months, respectively. Median PFS was 6.7 months, 9.0 months, not reached, not evaluable, 9.5 months, 5.5 months, not evaluable and 6.3 months, respectively. Median OS was 14.5 months, 13.5 months, not reached, 21.8 months, not evaluable, 17.6 months, not evaluable and 33.9 months, respectively. The most frequent (≥20% of patients) treatment-related adverse events were pyrexia (40.8%), fatigue (25.7%), chills (25.7%), nausea (23.8%) and rash (20.4%). The encouraging tumor-agnostic activity of dabrafenib plus trametinib suggests that this could be a promising treatment approach for some patients with BRAFV600E-mutated advanced rare cancers. ClinicalTrials.gov registration: NCT02034110 .

Published
2023

6. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

Author

Roland, Christina L., Nassif Haddad, Elise F., Keung, Emily Z., Wang, Wei-Lien, Lazar, Alexander J., Lin, Heather, Chelvanambi, Manoj, Parra, Edwin R., Wani, Khalida, Guadagnolo, B. Ashleigh, Bishop, Andrew J., Burton, Elizabeth M., Hunt, Kelly K., Torres, Keila E., Feig, Barry W., Scally, Christopher P., Lewis, Valerae O., Bird, Justin E., Ratan, Ravin, Araujo, Dejka, Zarzour, M. Alexandra, Patel, Shreyaskumar, Benjamin, Robert, Conley, Anthony P., Livingston, J. Andrew, Ravi, Vinod, Tawbi, Hussein A., Lin, Patrick P., Moon, Bryan S., Satcher, Robert L., Mujtaba, Bilal, Witt, Russell G., Traweek, Raymond S., Cope, Brandon, Lazcano, Rossana, Wu, Chia-Chin, Zhou, Xiao, Mohammad, Mohammad M., Chu, Randy A., Zhang, Jianhua, Damania, Ashish, Sahasrabhojane, Pranoti, Tate, Taylor, Callahan, Kate, Nguyen, Sa, Ingram, Davis, Morey, Rohini, Crosby, Shadarra, Mathew, Grace, Duncan, Sheila, Lima, Cibelle F., Blay, Jean-Yves, Fridman, Wolf Herman, Shaw, Kenna, Wistuba, Ignacio, Futreal, Andrew, Ajami, Nadim, Wargo, Jennifer A., and Somaiah, Neeta

Published
2024
Full Text
View/download PDF

7. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Author

Heinrich, Michael C., Jones, Robin L., George, Suzanne, Gelderblom, Hans, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Siontis, Brittany L., Goldstein, David, Boye, Kjetil, Sanchez, Cesar, Steeghs, Neeltje, Rutkowski, Piotr, Druta, Mihaela, Serrano, César, Somaiah, Neeta, Chi, Ping, Reichmann, William, Sprott, Kam, Achour, Haroun, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Blay, Jean-Yves, and Bauer, Sebastian

Published
2024
Full Text
View/download PDF

11. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Author

Duffaud, Florence, Blay, Jean-Yves, Le Cesne, Axel, Chevreau, Christine, Boudou-Rouquette, Pascaline, Kalbacher, Elsa, Penel, Nicolas, Perrin, Christophe, Laurence, Valérie, Bompas, Emmanuelle, Saada-Bouzid, Esma, Delcambre, Corinne, Bertucci, François, Cancel, Mathilde, Schiffler, Camille, Monard, Laure, Bouvier, Corinne, Vidal, Vincent, Gaspar, Nathalie, and Chabaud, Sylvie

Published
2023
Full Text
View/download PDF

15. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Author

Gounder, Mrinal M, Razak, Albiruni Abdul, Somaiah, Neeta, Chawla, Sant, Martin-Broto, Javier, Grignani, Giovanni, Schuetze, Scott M, Vincenzi, Bruno, Wagner, Andrew J, Chmielowski, Bartosz, Jones, Robin L, Riedel, Richard F, Stacchiotti, Silvia, Loggers, Elizabeth T, Ganjoo, Kristen N, Le Cesne, Axel, Italiano, Antoine, del Muro, Xavier Garcia, Burgess, Melissa, Piperno-Neumann, Sophie, Ryan, Christopher, Mulcahy, Mary F, Forscher, Charles, Penel, Nicolas, Okuno, Scott, Elias, Anthony, Hartner, Lee, Philip, Tony, Alcindor, Thierry, Kasper, Bernd, Reichardt, Peter, Lapeire, Lore, Blay, Jean-Yves, Chevreau, Christine, Morales, Claudia Maria Valverde, Schwartz, Gary K, Chen, James L, Deshpande, Hari, Davis, Elizabeth J, Nicholas, Garth, Gröschel, Stefan, Hatcher, Helen, Duffaud, Florence, Herráez, Antonio Casado, Beveridge, Roberto Diaz, Badalamenti, Giuseppe, Eriksson, Mikael, Meyer, Christian, von Mehren, Margaret, Van Tine, Brian A, Götze, Katharina, Mazzeo, Filomena, Yakobson, Alexander, Zick, Aviad, Lee, Alexander, Gonzalez, Anna Estival, Napolitano, Andrea, Dickson, Mark A, Michel, Dayana, Meng, Changting, Li, Lingling, Liu, Jianjun, Ben-Shahar, Osnat, Van Domelen, Dane R, Walker, Christopher J, Chang, Hua, Landesman, Yosef, Shah, Jatin J, Shacham, Sharon, Kauffman, Michael G, and Attia, Steven

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Genetics, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, Cancer, Child, Double-Blind Method, Humans, Hydrazines, Liposarcoma, Triazoles, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeAntitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.MethodsSEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461).ResultsTwo hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001).ConclusionPatients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.

Published
2022

16. Alveolar soft part sarcomas in young patients: The French national NETSARC+ network experience

Author

Genevois, Anne-Laure, Carton, Matthieu, Jean-Denis, Myriam, Cyrta, Joanna, Corradini, Nadège, Metayer, Lucy, Chemin-Airiau, Claire, Karanian, Marie, Dufresne, Armelle, Pannier, Stéphanie, El Zein, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Gantzer, Justine, Honoré, Charles, Noal, Sabine, Héritier, Sébastien, Guillemet, Cécile, Serre, Jill, Le Loarer, François, Pierron, Gaëlle, Merlin, Marie-Sophie, Anract, Philippe, Gomez-Mascard, Anne, Llacer, Carmen, Ducimetière, Françoise, Toulmonde, Maud, Blay, Jean-Yves, and Orbach, Daniel

Published
2024
Full Text
View/download PDF

17. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

Author

Blay, Jean-Yves, Devin, Quentin, Duffaud, Florence, Toulmonde, Maud, Firmin, Nelly, Collard, Olivier, Bompas, Emmanuelle, Verret, Benjamin, Ray-Coquard, Isabelle, Salas, Sebastien, Henon, Clemence, Honoré, Charles, Brahmi, Mehdi, Dufresne, Armelle, Pracht, Marc, Hervieu, Alice, Penel, Nicolas, Bertucci, Francois, Rios, Maria, Saada-Bouzid, Esma, Soibinet, Pauline, Perol, David, Chabaud, Sylvie, Italiano, Antoine, and Cesne, Axel Le

Published
2024
Full Text
View/download PDF

18. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO

Author

Blay, Jean-Yves, Penel, Nicolas, Toulmonde, Maud, Valentin, Thibaud, Chaigneau, Loic, Rios, Maria, Saada-Bouzid, Esma, Firmin, Nelly, Bertucci, Francois, Marec-Berard, Perrine, Ray-Coquard, Isabelle, Lervat, Cyril, Rolland, Frederic, Thyss, Antoine, Conroy, Thierry, Brahmi, Mehdi, Dufresne, Armelle, Merrouche, Yacine, Brunat-Mentigny, Maud, Biron, Pierre, Bompas, Emmanuelle, and Perol, David

Published
2024
Full Text
View/download PDF

19. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy

Author

Pasquali, Sandro, Vallacchi, Viviana, Lalli, Luca, Collini, Paola, Barisella, Marta, Romagosa, Cleofe, Bague, Silvia, Coindre, Jean Michel, Dei Tos, Angelo Paolo, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin-Broto, Javier, Lopez-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Beveridge, Robert Diaz, Casiraghi, Elena, Brich, Silvia, Renne, Salvatore Lorenzo, Bergamaschi, Laura, Vergani, Barbara, Sbaraglia, Marta, Casali, Paolo Giovanni, Rivoltini, Licia, Stacchiotti, Silvia, and Gronchi, Alessandro

Published
2024
Full Text
View/download PDF

21. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Loong, Herbert, Brunello, Antonella, Krieg, Andreas, Algulnik, Mark, Riedel, Richard, Okuno, Scott, Loggers, Elizabeth, Alcindor, Thierry, Ferraresi, Virginia, Serrano, César, Randall, R. Lor, Wilky, Breelyn, Ravi, Vinod, Gelderblom, Hans, Bhadri, Vivek, Stacchiotti, Silvia, Bauer, Sebastian, Wagner, Andrew J, van de Sande, Michiel, Bernthal, Nicholas M, López Pousa, Antonio, Razak, Albiruni Abdul, Italiano, Antoine, Ahmed, Mahbubl, Le Cesne, Axel, Tinoco, Gabriel, Boye, Kjetil, Martín-Broto, Javier, Palmerini, Emanuela, Tafuto, Salvatore, Pratap, Sarah, Powers, Benjamin C, Reichardt, Peter, Casado Herráez, Antonio, Rutkowski, Piotr, Tait, Christopher, Zarins, Fiona, Harrow, Brooke, Sharma, Maitreyi G, Ruiz-Soto, Rodrigo, Sherman, Matthew L, Blay, Jean-Yves, and Tap, William D

Published
2024
Full Text
View/download PDF

23. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Author

D'Angelo, Sandra P, Araujo, Dejka M, Abdul Razak, Albiruni R, Agulnik, Mark, Attia, Steven, Blay, Jean-Yves, Carrasco Garcia, Irene, Charlson, John A, Choy, Edwin, Demetri, George D, Druta, Mihaela, Forcade, Edouard, Ganjoo, Kristen N, Glod, John, Keedy, Vicki L, Le Cesne, Axel, Liebner, David A, Moreno, Victor, Pollack, Seth M, Schuetze, Scott M, Schwartz, Gary K, Strauss, Sandra J, Tap, William D, Thistlethwaite, Fiona, Valverde Morales, Claudia Maria, Wagner, Michael J, Wilky, Breelyn A, McAlpine, Cheryl, Hudson, Laura, Navenot, Jean-Marc, Wang, Tianjiao, Bai, Jane, Rafail, Stavros, Wang, Ruoxi, Sun, Amy, Fernandes, Lilliam, Van Winkle, Erin, Elefant, Erica, Lunt, Colin, Norry, Elliot, Williams, Dennis, Biswas, Swethajit, and Van Tine, Brian A

Published
2024
Full Text
View/download PDF

24. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

Author

Blay, Jean-Yves, Casali, Paolo, Ray-Coquard, Isabelle, Seckl, Michael J., Gietema, Jourik, de Herder, Wouter W., Caplin, Martyn, Klümpen, Heinz-Josef, Glehen, Olivier, Wyrwicz, Lucjan, Peeters, Robin, Licitra, Lisa, Girard, Nicolas, Piperno-Neumann, Sophie, Kapiteijn, Ellen, Idbaih, Ahmed, Franceschi, Enrico, Trama, Annalisa, Frezza, Anna-Maria, Hohenberger, Peter, Hindi, Nadia, Martin-Broto, Javier, Schell, Johanna, Rogasik, Muriel, Lejeune, Stephane, Oliver, Kathy, de Lorenzo, Francesco, and Weinman, Ariane

Published
2024
Full Text
View/download PDF

27. Radioligand therapies in cancer: mapping the educational landscape in Europe

Author

Bugani, Valentina, Battistelli, Luca, Sansovini, Maddalena, Monti, Manuela, Paganelli, Giovanni, Gich, Ignasi, Flotats, Albert, Erba, Paola Anna, Blay, Jean-Yves, la Fougère, Christian, Van Poppel, Hendrik, Charalambous, Andreas, Herrmann, Ken, Giordano, Alessandro, Györke, Tamás, Deroose, Christophe, Matteucci, Federica, and Carrió, Ignasi

Published
2023
Full Text
View/download PDF

30. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Author

Martin-Broto, Javier, Valverde, Claudia, Hindi, Nadia, Vincenzi, Bruno, Martinez-Trufero, Javier, Grignani, Giovanni, Italiano, Antoine, Lavernia, Javier, Vallejo, Ana, Tos, Paolo Dei, Le Loarer, Francois, Gonzalez-Campora, Ricardo, Ramos, Rafael, Hernández-Jover, Diana, Gutierrez, Antonio, Serrano, Cesar, Monteagudo, Maria, Letón, Rocio, Robledo, Mercedes, Moura, David S., Martin-Ruiz, Marta, López-Guerrero, Jose A., Cruz, Julia, Fernandez-Serra, Antonio, Blay, Jean-Yves, Fumagalli, Elena, and Martinez-Marin, Virginia

Published
2023
Full Text
View/download PDF

31. Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor

Author

Fu, Yu, Karanian, Marie, Perret, Raul, Camara, Axel, Le Loarer, François, Jean-Denis, Myriam, Hostein, Isabelle, Michot, Audrey, Ducimetiere, Françoise, Giraud, Antoine, Courreges, Jean-Baptiste, Courtet, Kevin, Laizet, Yech’an, Bendjebbar, Etienne, Du Terrail, Jean Ogier, Schmauch, Benoit, Maussion, Charles, Blay, Jean-Yves, Italiano, Antoine, and Coindre, Jean-Michel

Published
2023
Full Text
View/download PDF

32. The TLR3 L412F polymorphism prevents TLR3-mediated tumor cell death induction in pediatric sarcomas

Author

Bisaccia, Joseph, Meyer, Swann, Bertrand-Chapel, Adrien, Hecquet, Quentin, Barbet, Virginie, Kaniewski, Bastien, Léon, Sophie, Gadot, Nicolas, Rochet, Isabelle, Fajnorova, Iveta, Leblond, Pierre, Cordier-Bussat, Martine, Corradini, Nadège, Vasiljevic, Alexandre, Billaud, Marc, Picard, Cécile, Broutier, Laura, Gallerne, Cindy, Dutour, Aurélie, Blay, Jean-Yves, and Castets, Marie

Published
2023
Full Text
View/download PDF

33. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

Author

Kubicek, Pierre, Cesne, Axel Le, Lervat, Cyril, Toulmonde, Maud, Chevreau, Christine, Duffaud, Florence, Le Nail, Louis-Romée, Morelle, Magali, Gaspar, Nathalie, Vérité, Cécile, Castex, Marie-Pierre, Penel, Nicolas, Saada, Esma, Causeret, Sylvain, Bertucci, François, Perrin, Christophe, Bompas, Emmanuelle, Orbach, Daniel, Laurence, Valérie, Piperno-Neumann, Sophie, Anract, Philippe, Rios, Maria, Gentet, Jean-Claude, Mascard, Éric, Pannier, Stéphanie, Blouin, Pascale, Carrère, Sébastien, Chaigneau, Loïc, Soibinet-Oudot, Pauline, Corradini, Nadège, Boudou-Rouquette, Pascaline, Ruzic, Jean-Christophe, Lebrun-Ly, Valérie, Dubray-Longeras, Pascale, Varatharajah, Sharmini, Lebbe, Céleste, Ropars, Mickaël, Kurtz, Jean-Emmanuel, Guillemet, Cécile, Lotz, Jean-Pierre, Berchoud, Juliane, Cherrier, Grégory, Ducimetière, Françoise, Chemin, Claire, Italiano, Antoine, Honoré, Charles, Desandes, Emmanuel, Blay, Jean-Yves, Gouin, François, and Marec-Bérard, Perrine

Published
2023
Full Text
View/download PDF

36. Leiomyosarcoma and liposarcoma in young patients: The national netsarc+ network experience

Author

Genevois, Anne-Laure, Carton, Matthieu, Jean-Denis, Myriam, Cyrta, Joanna, Corradini, Nadège, Berlanga, Pablo, Chemin-Airiau, Claire, Honore, Charles, El Zein, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Anract, Philippe, Gantzer, Justine, Karanian, Marie, Rome, Angélique, Duffaud, Florence, Chevreau, Christine, Watson, Sarah, Le Cesne, Axel, Llacer, Carmen, Le Loarer, François, Pierron, Gaëlle, Gouin, François, Gomez-Mascard, Anne, Causeret, Sylvain, Ducimetière, Françoise, Kalbacher, Elsa, Toulmonde, Maud, Blay, Jean-Yves, and Orbach, Daniel

Published
2023
Full Text
View/download PDF

37. Prognostic factors of the synovial sarcoma of the extremities: imaging does matter

Author

Tordjman, Mickael, Honoré, Charles, Crombé, Amandine, Bouhamama, Amine, Feydy, Antoine, Dercle, Laurent, Haddag, Leila, Bouché, Pierre-Alban, Ngo, Carine, Le Cesne, Axel, Blay, Jean-Yves, Mir, Olivier, Brahmi, Mehdi, Martin, Charlotte, Karanian, Marie, Ammari, Samy, Kind, Michele, Audard, Virginie, Le Loarer, François, Rabiee, Behnam, Italiano, Antoine, Boudou-Rouquette, Pascaline, Biau, David, Balleyguier, Corinne, Larousserie, Frederique, Drapé, Jean-Luc, and Mihoubi, Fadila

Published
2023
Full Text
View/download PDF

39. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Author

Gelderblom, Hans, Jones, Robin L., Blay, Jean-Yves, George, Suzanne, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Siontis, Brittany L., Goldstein, David, Boye, Kjetil, Sanchez, Cesar, Steeghs, Neeltje, Rutkowski, Piotr, Druta, Mihaela, Serrano, César, Somaiah, Neeta, Chi, Ping, Harrow, Brooke, Becker, Claus, Reichmann, William, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C., and Bauer, Sebastian

Published
2023
Full Text
View/download PDF

42. Sarcomes du stroma endométrial de bas grade : référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG

Author

Lebreton, Coriolan, Meeus, Pierre, Genestie, Catherine, Croce, Sabrina, Guyon, Frédéric, Moscardo, Carmen Llacer, Taieb, Sophie, Blay, Jean-Yves, Bonvalot, Sylvie, Bompas, Emmanuelle, Chevreau, Christine, Lécuru, Fabrice, Rossi, Léa, Joly, Florence, Rios, Maria, Chaigneau, Loïc, Duffaud, Florence, Pautier, Patricia, and Ray-Coquard, Isabelle

Published
2023
Full Text
View/download PDF

45. Occupational asbestos exposure and survival among lung cancer patients

Author

Noelle, Hugo, Pérol, Olivia, Pérol, Maurice, Avrillon, Virginie, Belladame, Elodie, Fayette, Jérôme, Fournié, Françoise, Swalduz, Aurélie, Dessemon, Juliette, Blay, Jean-Yves, Neidhardt, Eve-Marie, Saintigny, Pierre, Tabutin, Mayeul, Boussageon, Maxime, Praud, Delphine, Charbotel, Barbara, and Fervers, Beatrice

Published
2023
Full Text
View/download PDF

47. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022

Author

Andreou, Dimosthenis, Barth, Thomas, Bauer, Sebastian, Blay, Jean-Yves, Blum, Veronika, Bode, Beata, Bonvalot, Sylvie, Bovee, Judith, Braam, Petra, Brodowicz, Thomas, Broto, Jean Martin, Dei Tos, Angelo, Denschlag, Dominik, Desar, Ingrid, Digklia, Antonia, Dileo, Palma, Dirksen, Uta, Douchy, Thomas, Duffaud, Florence, Eriksson, Mikael, Fröhling, Stefan, Gelderblom, Hans, Gronchi, Alessandro, Haas, Rick, Hardes, Jenrik, Hartmann, Wolfgang, Hofer, Silvia, Hohenberger, Peter, Hompes, Daphne, Huang, Paul, Italiano, Antoine, Jakob, Jens, Jones, Robin, Judson, Ian, Köhler, Günter, Kollàr, Attila, Krasniqi, Fatime, Krol, Stijn, Kunz, Wolfgang, Le Grange, Franel, Le Pechoux, Cécile, LeCesne, Alexandre, Leithner, Andreas, Liegl-Atzwanger, Bernadette, Lindner, Lars, Mechtersheimer, Gunhild, Messiou, Christina, Miah, Aisha, Pink, Daniel, Reichardt, Peter, Romagosa, Cleo, Rothermundt, Christian, Rutkowski, Piotr, Safwat, Akmel, Sangalli, Claudia, Szkandera, Joanna, Thway, Khin, Tunn, Per-Ulf, Van der Graaf, Winette, Van Houdt, Winan, Wardelmann, Eva, Zachariah, Ralph, Botter, Sander, Cerny, Thomas, Desar, Ingrid M.E., Jones, Robin L., Kunz, Wolfgang G., Liegl-Atzwanger, Berndadette, Lindner, Lars H., Miah, Aisha B., van der Graaf, Winette T.A., and van Houdt, Winan J.

Published
2023
Full Text
View/download PDF

49. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

Author

Bouttefroy, Séverine, Penel, Nicolas, Orbach, Daniel, Minard-Colin, Véronique, Le Cesne, Axel, Blay, Jean-Yves, Marec-Berard, Perrine, Verité, Cécile, Laurence, Valérie, Piperno-Neumann, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Chevreau, Christine, Duffaud, Florence, Salas, Sébastien, Morelle, Magali, Jean-Denis, Myriam, Italiano, Antoine, Bonvalot, Sylvie, and Corradini, Nadège

Published
2023
Full Text
View/download PDF

50. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts

Author

Stacchiotti, Silvia, Dürr, Hans Roland, Schaefer, Inga-Marie, Woertler, Klaus, Haas, Rick, Trama, Annalisa, Caraceni, Augusto, Bajpai, Jyoti, Baldi, Giacomo Giulio, Bernthal, Nicholas, Blay, Jean-Yves, Boye, Kjetil, Broto, Javier-Martin, Chen, Wei-Wu Tom, Dei Tos, Paolo Angelo, Desai, Jayesh, Emhofer, Stephan, Eriksson, Mikael, Gronchi, Alessandro, Gelderblom, Hans, Hardes, Jendrik, Hartmann, Wolfgang, Healey, John, Italiano, Antoine, Jones, Robin L., Kawai, Akira, Leithner, Andreas, Loong, Herbert, Mascard, Eric, Morosi, Carlo, Otten, Nadine, Palmerini, Emanuela, Patel, Shreyaskumar R., Reichardt, Peter, Rubin, Brian, Rutkowski, Piotr, Sangalli, Claudia, Schuster, Kathrin, Seddon, Beatrice M., Shkcodra, Morena, Staals, Eric L., Tap, William, van de Rijn, Matt, van Langevelde, Kirsten, Vanhoenacker, Filip M.M., Wagner, Andrew, Wiltink, Lisette, Stern, Sydney, Van de Sande, Michiel, and Bauer, Sebastian

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results